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Aging is associated with an increase in systolic blood
pressure, a decline in active renin concentration, and
an increase in the level of sympathetic nervous system
activity.1 Although the pathogenesis of hypertension in
the elderly is unknown, older patients with hyperten-
sion are characterized by increased sympathetic ner-
vous system activity, enhanced a -adrenergic receptor
responsiveness,2 and low active renin concentration.1
The pathophysiology of hypertension in the elderly may
therefore involve altered regulation of sympathetic ner-
vous system function.
The renin-angiotensin system has important interac-
tions with the sympathetic nervous system. Angiotensin
II has been shown to facilitate norepinephrine release
from nerve terminals, block norepinephrine reuptake,
elevate catecholamine synthesis, and potentiate the
postsynaptic action of norepinephrine.3-5 In humans,
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plasma norepinephrine levels and muscle sympathetic
activity have been shown to decrease in healthy sub-
jects and in patients with hypertension and congestive
heart failure who were treated with angiotensin-
converting enzyme (ACE) inhibitors.6-8 ACE inhibition
may therefore decrease sympathetic nervous system
activity.
The objective of this study was to test the hypothe-
sis that long-term ACE inhibition by ramipril will sup-
press sympathetic nervous system activity and up-
regulate a -adrenergic receptor responsiveness in older
patients with hypertension. A minimal 2-compartment
model was used to determine the parameters of norepi-
nephrine kinetics, including the rate of norepinephrine
release into the extravascular compartment (NE2) as
an estimate of systemic sympathetic nervous system
activity. a -Adrenergic receptor responsiveness was
determined by norepinephrine-mediated forearm vaso-
constriction and by platelet a 2-receptor–mediated
inhibition of adenylyl cyclase. We report that ramipril
therapy does not suppress systemic sympathetic ner-
vous system activity, alter other norepinephrine kinetic
parameters, or alter a -adrenergic responsiveness in
older patients with hypertension.
METHODS
Subjects. Fifteen older subjects (10 men and 5
women; age range, 60 to 75 years; mean age ± SD, 64
± 3 years) with mild to moderate hypertension in oth-
erwise good general health were recruited through the
Human Subjects Core of the University of Michigan
Geriatrics Center and through newspaper advertise-
ment. Each subject was screened before study entry
with a medical history, physical examination, and lab-
oratory tests, including a complete blood count, routine
chemistries, and an ECG. Subjects were excluded from
participation if they exceeded 150% of ideal body
weight (Metropolitan Life Insurance tables, 1983);
were being treated with either a - or b -adrenergic med-
ications; had evidence for secondary hypertension dis-
covered by routine clinical evaluation; had any history
of angina, previous myocardial infarction, transient
ischemic attack, previous stroke, claudication, syncope,
diabetes mellitus, or Parkinson’s disease; or had evi-
dence from either history, physical examination, or lab-
oratory results of other significant underlying medical
or psychiatric illness. Subjects were either not receiv-
ing antihypertensive therapy or were receiving
monotherapy. Subjects were eligible for the study if,
after a 4-week observational period or withdrawal of
antihypertensive therapy, their diastolic blood pressure
measurements remained between 90 and 115 mm Hg
and systolic blood pressure measurements remained
below 220 mm Hg when blood pressure measurements
were taken on 3 separate occasions while they were sit-
ting. The study was approved by the University of
Michigan Human Use Committee, and each subject
provided written informed consent.
Study protocol. The subjects were randomized in
double-blind fashion into an intervention and control
group by use of block randomization, with the ratio of
intervention to placebo control of 2:1. Treatment with
ramipril or placebo began after the 4-week run-in
period during which subjects receiving antihyperten-
sive therapy were withdrawn from their previous anti-
hypertensive therapy. The subjects randomized to the
intervention group were treated with ramipril starting
at 10 mg/day. The dose was increased by 10 mg every
week until the blood pressure target of less than 140/90
mm Hg was achieved or a maximum dose of 40 mg/day
ramipril was reached. The subjects randomized to the
placebo group received matching placebo tablets that
were increased by 1 tablet every week up to a maxi-
mum of 4; that dose was then maintained for 4 weeks.
Studies were performed at the beginning and end of
the 8-week treatment period. All subjects reported to
the General Clinical Research Center of the University
of Michigan Medical Center at 7:30 AM to control for
any diurnal variation in norepinephrine metabolism9 or
arterial a -adrenergic tone.10 They were instructed to
fast from 10 PM the night before and to abstain from
cigarettes, caffeine, and other known modulators of cat-
echolamines for 12 hours before each study began. Sub-
jects were studied while in the supine position in a quiet
room maintained at a constant temperature from 23°C
to 25°C to facilitate achieving an adequate baseline
forearm blood flow (FABF). The proportion of body fat
was determined by bioelectrical impedance (RJL Sys-
tems, Mt Clemens, Mich)11 and the waist/hip ratio was
determined from an individual’s waist and hip circum-
ferences taken at the level of the umbilicus and the
largest gluteal circumference, respectively. Forearm
volume was measured with use of water displacement.
Systemic norepinephrine kinetics protocol. A 20-
gauge 1⁄4-inch Insyte catheter was placed into the
brachial artery of the nondominant arm. The catheter
was connected to a pressure transducer (Hewlett-
Packard 1290A quartz transducer, Hewlett-Packard,
Andover, Mass). Mean arterial pressure (MAP) was
determined from the electronically integrated area
under the intra-arterial blood pressure curve from the
Marquette telemetry system (Marquette Electronics
Series 7700, Marquette Electronics, Inc, Milwaukee,
Wis). An intravenous catheter was placed in the con-
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tralateral arm for infusion of [3H]norepinephrine.
Before this infusion was begun, venous blood drawn
from this site was collected into a plastic syringe that
contained 1 mL of 0.25 mol/L ethylenediaminete-
traacetic acid to be used to prepare platelet membranes.
The [3H]norepinephrine kinetics protocol was carried
out as described previously with sampling from the
brachial arterial catheter.12,13 Ten-milliliter blood sam-
ples were obtained (after discarding the first 1 mL
blood from the line) at 40, 50, and 60 minutes during
the infusion to determine plasma norepinephrine and
[3H]norepinephrine concentrations. At 60 minutes, the
[3H]norepinephrine infusion was stopped, and 10 mL
blood samples were obtained at 1, 2, 4, 6, 8, 10, 12, 14,
16, 18, and 20 minutes to measure [3H]norepinephrine
concentration. One of the 3 basic ECG limb leads was
monitored.
Forearm blood flow protocol. Following the tracer
[3H]norepinephrine infusion protocol, FABF was mea-
sured with use of venous occlusion plethysmography
during an intra-arterial infusion protocol we have
described previously.12,13 To establish a stable baseline,
FABF readings were taken until 3 consecutive readings
that represented similar FABF were obtained. To deter-
mine the effect of intra-arterial infusions of norepi-
nephrine on FABF, norepinephrine (Levophed bitar-
trate, Sterling Drug Inc, New York, NY) was diluted in
5% dextrose to achieve stepwise increasing infusion
doses of 1.25, 5, 20, 80, and 240 ng/100 mL forearm
volume/min. Each norepinephrine dose was adminis-
tered by an infusion pump (Harvard model 970T; Har-
vard Apparatus, South Natick, Mass) for 4 minutes
before FABF was recorded during the fifth minute of
each infusion. After the FABF measurement at the 240-
ng dose, the norepinephrine infusion was stopped.
Platelet membrane preparation. Platelet membrane
lysates were prepared from 50 to 200 mL whole venous
blood as described previously.14,15 An aliquot of the
freshly prepared membrane lysate was used for adenylyl
cyclase assays. The remainder of the sample was quick
frozen in liquid nitrogen and stored at –70°C; radioli-
gand binding studies were performed within 2 weeks
of membrane preparation.
Radioligand equilibrium binding assays. [methyl-
l,3H]Yohimbine (72.5-90.0 Ci/mmol; Amersham,
Arlington Heights, Ill), a specific a 2-adrenergic recep-
tor antagonist, was used to determine platelet membrane
a 2-adrenergic receptor antagonist binding properties
and the imidazoline full a 2-2-adrenergic receptor ago-
nist [3H]-5bromo-6-N(2-4,5-dihydroimidazolyl) quinox-
aline ([3H]UK 14,304 or [3H]bromoxidine; 60.0 to 93.9
Ci/mmol, New England Nuclear, Boston, Mass) was
used to determine platelet membrane a 2-adrenergic
receptor agonist binding properties with use of meth-
ods we have described previously.14 In human platelet
membranes, [3H]bromoxidine has been shown to bind
to 1 high-affinity site,16 which is functionally coupled
to adenylyl cyclase.17 We have previously shown that
analysis of [3H]bromoxidine specific binding over the
concentration range and assay conditions used in these
experiments identifies the high-affinity binding state.14
Adenylyl cyclase assays. Platelet membrane basal
adenylyl cyclase activity was determined with use of
freshly prepared membranes at the beginning (time 0)
and at the conclusion of a 15-minute incubation at 30°C
as described previously.14,15 Stimulation of adenylyl
cyclase activity was achieved with the addition of 25-
mmol/L sodium fluoride (NaF) and its a 2-adrenergic
receptor–medicated inhibition by 10-9 to 10-4 mol/L
epinephrine. The concentration of cAMP in the assay
tubes was measured by radioimmunoassay.15 The con-
centration of cAMP in the 0-time basal activity condi-
tion was subtracted from the 15-minute basal, NaF-
stimulated, and epinephrine inhibition conditions so
that the values would reflect only the accumulation of
cAMP during the 15-minute incubation period. The
extent of epinephrine-mediated inhibition at each epi-
nephrine concentration was determined as the percent-
age decrease in cAMP accumulation in the presence of
epinephrine and NaF from the NaF-stimulated activity
without epinephrine.
Plasma catecholamine analytical methods. Arterial
or arterialized-venous blood samples were collected into
chilled plastic tubes that contained ethylene glycol-
bis(B-aminoethyl ether)-N,N,N´,N´-tetraacetic acid
(EGTA) and reduced glutathione. The tubes were kept
on ice until centrifugation at 4°C. Plasma samples were
stored at –70°C until assayed. Plasma norepinephrine
and epinephrine were quantified by a single-isotope
radioenzymatic assay, with all samples from a given
subject analyzed in the same assay.18 The intra-assay
coefficient of variation for norepinephrine in this assay
is 5%. Alumina extraction of plasma samples and mea-
surement of [3H]norepinephrine levels were performed
as described previously.19,20
Data and statistical analysis. Steady-state, 1-com-
partment, kinetic parameters (the rate of appearance
into [NEAP] and clearance from [NECL] the circulation)
were calculated from steady-state plasma levels of 3H-
norepinephrine and norepinephrine as described previ-
ously.19 Compartmental analysis of norepinephrine
kinetics was performed with the previously described
minimal 2-compartment model.19 The quantity of nor-
epinephrine in each compartment (norepinephrine mass
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in the intravascular compartment [Q1] and in the
extravascular compartment [Q2]), the rate of norepi-
nephrine appearance into each compartment (R12 into
compartment 1 and NE2 into compartment 2), the nor-
epinephrine metabolic clearance rate from compart-
ment 1 (MCR1), the norepinephrine spillover fraction
(NESF), and the volume of distribution of norepineph-
rine in compartment 1 (V1) were calculated from the 2-
compartment model as functions of the estimated trans-
fer rate coefficients as described previously.19
Baseline and posttreatment changes within each
group were compared by the paired Student t tests.
Heart rate, MAP, norepinephrine kinetic parameters,
platelet membrane adenylyl cyclase activity, and equi-
librium binding studies were analyzed with SAS (SAS
Institute, Inc, Cary, NC). To adjust for any existing dif-
ferences in baseline values between the control and
intervention groups, multiple regression models, which
included the baseline values as a covariate, were cre-
ated to compare the posttreatment values between inter-
vention (ramipril) and control (placebo) groups.
Dose-response data for norepinephrine was analyzed
as the percentage change in FABF from the baseline
value obtained before the infusion with use of repeated-
measures ANOVA. MAP was determined just before
each FABF measurement. Forearm vascular resistance
was calculated as the MAP divided by the FABF and
is presented in arbitrary units. Dose-response curves
for adenylyl cyclase inhibition by epinephrine were also
analyzed by ANOVA between baseline and post-
ramipril treatment groups.
Values are presented as mean values ± SEM except
for the subject characteristics, which are presented as
mean values ± SD. A value of P < .05 was selected to
indicate statistical significance. Paired Student t tests
were used to compare differences in age, body mass
index, waist/hip ratio, percent body fat, MAP, and heart
rate between the control and intervention groups.
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Table I. Hemodynamic characteristics
Intervention (n = 11) Control (n = 4)
Baseline Ramipril P Value Baseline Placebo P Value
MAP (mm Hg) 119 ± 4 112 ± 5 .01 127 ± 6 130 ± 9 .34
Heart rate (beats/min) 64 ± 3 63 ± 2 .26 74 ± 7 76 ± 6 .53
FABF (mL/min) 3.6 ± 0.5 3.6 ± 0.4 .95 4.9 ± 1.3 6.3 ± 0.2* .92
FAVR (units)† 41 ± 7 35 ± 3 .28 32 ± 8 21 ± 2 .71
MAP, Mean arterial blood pressure, derived from supine intra-arterial blood pressure recording; FABF, forearm blood flow.
*n = 2.
†FAVR, Mean arterial blood pressure/FABF.
Table II. Plasma catecholamines and norepinephrine kinetic parameters
Intervention (n = 10) Control (n = 3)
Baseline Ramipril P Value Baseline Placebo P Value
Plasma norepinephrine (pg/mL) 359 ± 36 396 ± 41 .01 350 ± 19 349 ± 37 .98
Plasma epinephrine (pg/mL) 64 ± 10 52 ± 4 .44 46 ± 10 55 ± 10 .14
One-compartment model
NEAP (m g/min/m2) 0.37 ± 0.04 0.43 ± 0.05 .38 0.38 ± 0.04 0.42 ± 0.05 .63
NECL (mL/min/m2) 2074 ± 99 2037 ± 119 .81 2503 ± 129 2400 ± 104 .57
Two-compartment model
NE2 (m g/min/m2) 2.81 ± 0.35 2.84 ± 0.32 .92 2.25 ± 0.16 2.63 ± 0.20 .11
MCR1 (mL/min/m2) 1114 ± 52 1073 ± 50 .41 1211 ± 38 1186 ± 95 .86
Q1 (m g/m2) 0.49 ± 0.08 0.48 ± 0.06 .90 0.40 ± 0.03 0.52 ± 0.12 .28
Q2 (m g/m2) 75 ± 11 94 ± 35 .63 45 ± 3 68 ± 3 .29
NESF (%) 14 ± 0.9 14 ± 1 .95 17 ± 1 16 ± 2 .63
V1 (L/m2) 2.7 ± 0.3 2.5 ± 0.2 .51 2.5 ± 1 2.9 ± 0.3 .39
Data are mean values ± SEM.
NEAP, Rate of norepinephrine appearance into circulation; NECL, rate of norepinephrine clearance from circulation; NE2, extravascular norepinephrine release rate;
MCR1, norepinephrine metabolic clearance rate from compartment 1; Q1 and Q2, norepinephrine mass in compartments 1 and 2; NESF, norepinephrine spillover frac-
tion; V1, norepinephrine volume of distribution in compartment 1; compartment 1, vascular-containing compartment; compartment 2, extravascular compartment.
ment differences between the ramipril group compared
with the placebo group for either plasma norepineph-
rine (P = .25) or epinephrine levels (P = .19). No inter-
actions were identified between the groups and the
baseline measurements. Norepinephrine kinetics results
were not obtained from 1 ramipril subject and 1 placebo
subject because of technical difficulties. Analysis of
steady-state norepinephrine kinetics with the 1-com-
partment model showed no significant differences in
the ramipril group compared with the placebo group
for NEAP or NECL, even after adjustments were made
for the baseline measurements (NEAP, P = .76; NECL,
P = .92). There were no treatment effects noted for NE2,
MCR1, norepinephrine mass in compartments 1 or 2,
norepinephrine spillover fraction, or the norepineph-
rine volume of distribution after treatment within the
ramipril group and placebo group separately or among
the 2 groups when adjusted for baseline.
FABF during vasoactive infusions. There were no
ramipril–placebo group differences in either baseline
FABF (P = .27) or forearm vascular resistance (P = .48)
measured before the intra-arterial infusion protocol
(Table I). The change in FABF at baseline and after
treatment in response to each norepinephrine intra-
arterial infusion dose is shown for the ramipril group
(Figure 1). There was a significant norepinephrine dose
effect (P < .0001). However, there was no significant
difference in the percentage change in FABF between
baseline and post-ramipril treatment (ANOVA, P =
.97). Complete norepinephrine dose-response results
were not available for 1 subject in the ramipril group
and 2 subjects in the placebo group. Among the sub-
jects receiving placebo, there was a similar norepineph-
rine dose effect and no apparent baseline-placebo dif-
ference in percentage change in FABF, but statistical
analysis was not performed because only 2 subjects in
the placebo group completed this protocol.
Platelet membrane adenylyl cyclase activity. There
were no significant group differences (P = .61) in the
basal rate of cAMP production in the platelet membrane
lysates during the 15-minute incubation period (after
subtracting the cAMP concentration present in the
membrane samples at time 0 of the assay; Table III). In
addition, the degree of stimulation above the basal level
by NaF was also similar between the 2 groups when
adjusted for the baseline measurements (P = .86). The
dose-response effect for epinephrine-mediated inhibi-
tion of NaF-stimulated adenylyl cyclase activity identi-
fied a significant dose effect for epinephrine-mediated
inhibition, but no significant difference between the
baseline measures and either after ramipril (ANOVA,
P = .79) or after placebo (ANOVA, P = .66) for the per-
424 Lee et al
CLINICAL PHARMACOLOGY & THERAPEUTICS
APRIL 1999
RESULTS
Subject characteristics. Ten men and 5 women par-
ticipated in the study. The mean age of these subjects
was 65 years, with an age range from 60 to 73 years.
The subject group was somewhat overweight as
reflected in their body mass index (28.1 ± 3.5 kg/m2),
waist/hip ratio (0.87 ± 0.09), and percentage of body fat
(28.6% ± 7.0%). There were no statistically significant
differences with respect to age, gender distribution,
body mass index, waist/hip ratio, or percentage of body
fat between the control and intervention subject groups.
Hemodynamic characteristics. The ramipril dose
achieved in the treatment group ranged from 5 to 20 mg,
with a mean dose of 12 ± 2 mg. Treatment with ramipril
significantly decreased MAP (P = .01), whereas treat-
ment with placebo did not significantly change the MAP
in the control group (P = .34; Table I). The placebo
group tended to have a higher baseline heart rate and
MAP compared with the intervention group, but these
differences were not statistically significant.
Plasma catecholamine levels and systemic norepi-
nephrine kinetics. There was a significant increase in
plasma norepinephrine levels within the ramipril group
after 8 weeks of ramipril therapy that was not observed
in the placebo group (Table II). However, when the sta-
tistical analysis is adjusted for the baseline measure-
ments with multiple regression, there were no posttreat-
Figure 1. Group mean data for percentage change of fore-
arm blood flow (FABF) from baseline in response to increas-
ing doses of intra-arterial norepinephrine (NE) infusion in
older subjects with hypertension at baseline and after 8 weeks
of ramipril. A significant treatment effect was not shown by
ANOVA (P = .97). FAV, Forearm volume.
centage of inhibition from the NaF-stimulated level.
There were also no significant differences in the maxi-
mal extent of adenylyl cyclase inhibition (Table III).
Equilibrium binding studies. The receptor binding
densities and dissociation constants from equilibrium
binding studies for the antagonist [3H]yohimbine and
the agonist [3H]bromoxidine are presented in Table III.
An insufficient platelet protein yield prevented [3H]bro-
moxidine studies from being done in 2 subjects in the
ramipril group and 2 subjects in the placebo group.
When the baseline measurements are accounted for
with regression analysis, there were no significant post-
treatment group differences in the maximum receptor
binding density (Bmax) or dissociation constant (Kd) for
either the antagonist radioligand [3H]yohimbine (Bmax,
P = .22; Kd, P = .20) or the agonist radioligand [3H]bro-
moxidine (Bmax, P = .48; Kd, P = .80).
DISCUSSION
The results from this study do not support the
hypothesis that ramipril suppresses sympathetic ner-
vous system activity in older patients with hyperten-
sion. After 8 weeks of ramipril therapy, there was a sig-
nificant reduction in blood pressure, whereas no change
in blood pressure was identified in the placebo-treated
control group. Although plasma norepinephrine levels
increased in the ramipril treated subjects, the findings
from the norepinephrine kinetics studies in these sub-
jects did not show an increase in NE2, the rate of nor-
epinephrine release into the extravascular compartment.
These findings were consistent with the 1-compartment
model analysis, showing no difference in NEAP
between the ramipril and placebo groups. In addition,
there was no significant effect of ramipril on other nor-
epinephrine kinetic parameters. Consistent with the
lack of change in sympathetic nervous system activity,
the results did not show any effect of ramipril on the
adrenergic-mediated decrease in FABF or inhibition of
platelet membrane adenylyl cyclase activity.
Animal and human studies have shown interactions
between the sympathetic nervous system and the renin-
angiotensin system. In isolated rat mesenteric arteries,
Malik and Nasjletti4 demonstrated that angiotensin II
potentiates the vasoconstrictor responses to sympathetic
nerve stimulation and to injected norepinephrine. With
use of in vivo and in vitro techniques, Clough et al5
showed in rats that angiotensin II facilitates adrenergic
neurotransmission and that inhibitors of the renin-
angiotensin system attenuate neurogenic vasoconstric-
tion. Consistent with these observations, several studies
have suggested that therapy with ACE inhibitors may
decrease sympathetic nervous system activity. Noll6
found that muscle sympathetic activity decreased after
single-dose captopril administration in healthy volun-
teers. Plasma norepinephrine levels were also found to
be decreased in patients with hypertension treated with
quinapril,7 captopril,21 or single-dose benazepril.8 Other
studies have failed to identify changes in plasma norep-
inephrine level immediately following22-24 or after
short-term25,26 ACE inhibitor therapy.
The results from these studies led us to hypothesize
that long-term ACE inhibitor therapy with ramipril
would decrease systemic sympathetic nervous system
activity in older patients with hypertension. We chose
this study population, which is characterized by rela-
tively high levels of sympathetic nervous system activ-
ity, to increase the likelihood of detecting suppression
of sympathetic nervous system activity.2 In contrast to
the studies cited above, we elected to characterize
response to long-term (8 weeks) as opposed to acute
single-dose therapy. In addition, recognizing the com-
plex metabolism of norepinephrine, we performed nor-
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Table III. Platelet membrane a 2-receptor binding characteristics and adenylyl cyclase activity
Intervention (n = 11) Control (n = 4)
Baseline Ramipril P Value Baseline Placebo P Value
Platelet membrane a 2-receptor binding characteristics
Yohimbine Bmax (fmol/mg protein) 144 ± 14 115 ± 12 .11 105 ± 13 119 ± 20 .56
Yohimbine Kd (pmol/L) 2.1 ± 0.2 1.6 ± 0.1 .01 1.5 ± 0.09 1.8 ± 0.03 .04
Bromoxidine Bmax (fmol/mg protein) 33.0 ± 6.4 23.9 ± 6.0 .02 17 ± 9.4 8.8 ± 5.2 .90
Bromoxidine Kd (nmol/L) 2.8 ± 0.6 1.9 ± 0.3 .34 1.7 ± 0.2 1.8 ± 0.7 .89
Platelet membrane adenylyl cyclase activity
Basal (pmol/mg/15 min) 570 ± 76 517 ± 51 .55 648 ± 121 459 ± 160 .37
NaF-stimulated (pmol/mg/15 min) 2185 ± 189 2050 ± 135 .39 2451 ± 247 2085 ± 464 .54
Maximal epinephrine-mediated inhibition (%) –50.9 ± 4.3 –53.9 ± 1.2 .49 –53.3 ± 2.0 –62.4 ± 2.4 .13
Bmax, Maximum receptor binding density; Kd, dissociation constant; NaF, sodium fluoride.
epinephrine kinetics studies to avoid reliance on plasma
norepinephrine levels to reflect sympathetic nervous
system activity. We report that plasma norepinephrine
levels increased after 8 weeks of therapy with ramipril.
However, there was no significant increase in the rate
of norepinephrine release into the extravascular com-
partment (NE2), nor were there significant differences
in other parameters of norepinephrine metabolism. The
increase in plasma norepinephrine levels may be
accounted for by the slight, although not statistically
significant, reductions in MCR1 and V1. We therefore
conclude that long-term ACE inhibition by ramipril
appears to have no effect on systemic sympathetic ner-
vous system activity in older patients with hypertension.
To the extent that no change in sympathetic nervous
system activity was identified in our subjects, it follows
that there were no significant differences in the mea-
sures of a 2-receptor responsiveness. There were no sig-
nificant changes in resting forearm blood flow or fore-
arm vascular resistance after ramipril therapy. The
effect of intrabrachial artery norepinephrine infusion to
decrease forearm blood flow was similar to baseline
after ramipril therapy. Many studies have used platelet
a 2-adrenergic-receptors as an accessible model of vas-
cular a -adrenergic receptor function.27 To that end, in
parallel with the vascular responsiveness results, there
was also no effect of ramipril therapy on a 2-mediated
inhibition of platelet membrane adenylyl cyclase activ-
ity. This was the case despite a tendency for there to be
reduction in both total (yohimbine Bmax) and high-
affinity (bromoxidine Bmax) receptor binding densities.
These slight reductions in receptor binding densities
might have resulted from the increase in plasma nor-
epinephrine levels after ramipril therapy because expo-
sure of platelets to increased plasma norepinephrine
would be expected to regulate their a 2-receptor func-
tion. One study has also reported a reduction in total
platelet a 2-receptor density after 16 weeks of therapy
with captopril; however, no change in plasma norepi-
nephrine levels was observed in this group.21 Additional
studies will be required to determine whether the
absence of change in a 2-mediated inhibition of adeny-
lyl cyclase reflects abnormal a 2-receptor regulation or
insufficient exposure to agonist.
We acknowledge several potential limitations inher-
ent in our study. Although conducted in a placebo-
controlled, double-blind randomized manner, this study
did not test for a change in sympathetic nervous sys-
tem activity during a comparable reduction in blood
pressure with an agent that does not affect the renin-
angiotensin system. It might be expected that sympa-
thetic nervous system activity would be increased with
blood pressure reduction. Therefore we cannot exclude
the possibility that there was a sympatholytic effect of
ACE inhibition that prevented an increase in sympa-
thetic nervous system activity. The results in this study
may be specific to the ACE inhibitor ramipril and may
not necessarily generalize to other ACE inhibitors. In
addition, the norepinephrine kinetics study we con-
ducted provides an assessment of systemic but not
regional level of sympathetic nervous system activity.
We cannot rule out the possibility that ramipril therapy
led to suppression of regional, organ-specific sympa-
thetic nervous system activity, without affecting over-
all systemic level of activity.
In summary, we did not find that long-term ramipril
therapy suppresses systemic sympathetic nervous sys-
tem activity in older patients with hypertension. The
2-compartment model analysis of systemic norepineph-
rine kinetics showed that there were no changes in NE2,
norepinephrine clearance, norepinephrine spillover
fraction, or the norepinephrine volume of distribution.
Despite an increase in plasma norepinephrine levels,
the stability of the rate of norepinephrine release into
the extravascular compartment (NE2) supports the con-
clusion that there was no change in sympathetic ner-
vous system activity with ramipril therapy. Consistent
with this, there was no apparent change in vascular or
platelet a -adrenergic receptor responsiveness. On the
basis of these results, we conclude that the blood
pressure–lowering effect of ramipril in older subjects
with hypertension occurs independently of effects on
sympathetic nervous system function.
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